drugset / Trial / NCT04564898
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NaSingle-groupOpen-labelTreatment
Summary
The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC patients who are deemed not eligible for intensive chemotherapy (part 2, expansion phase).
Timeline
- Start
- 2022-01-25
- Primary completion
- 2024-05-29
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Trifluridine/Tipiracil | Unknown | 25 mg/m2 | Oral |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | Oral |